Henry Schein investor flows in focus, mixed analyst view on shares

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 16:09.

Henry Schein (US42548G1040) sits on NASDAQ with a solid healthcare distribution profile and a valuation shaped increasingly by institutional flows. The latest filings highlight a sizable position shift by SG Americas Securities alongside a still cautious analyst consensus, according to recent market commentary.

What recent filings show

MarketBeat reports that SG Americas Securities LLC held 606,492 Henry Schein shares worth about 44.7 million US dollars at the end of the first quarter, after cutting its stake by roughly 26.1 percent in the period according to a June 23 MarketBeat report. The filing underscores that Henry Schein remains a meaningful institutional position, even as some holders trim exposure.

The same report points out that Henry Schein previously delivered quarterly earnings per share of 1.32 US dollars, ahead of the 1.20 dollar consensus, on revenue of 3.37 billion dollars, up 6.3 percent year-on-year based on the same MarketBeat data. That quarter produced a return on equity of around 15.4 percent and a net margin close to 3 percent, marking a business that grows steadily but operates on relatively tight margins.

Analyst stance and valuation frame

Analysts summarized by MarketBeat assign Henry Schein a consensus Hold rating with an average price target of 87.85 US dollars, reflecting only moderate expected upside from recent trading levels according to MarketBeat analyst consensus data. Recent research actions include a mixture of price target cuts and upgrades from firms such as Mizuho and BTIG, underlining the divided view on near-term performance.

MarketBeat also notes that the company has set a full-year 2026 earnings guidance range of 5.23 to 5.37 US dollars per share, while sell-side forecasts cluster around 5.32 dollars for the current year based on listed guidance and estimates. For investors following S&P 500 healthcare distributors such as McKesson or Cardinal Health as peers, Henry Schein’s guided EPS corridor and Hold consensus frame a stock positioned between growth expectations and valuation discipline.

The business behind Henry Schein

Henry Schein generates most of its revenue from distributing dental and medical supplies, equipment and related services to practices and clinics worldwide, including the United States and Europe as outlined in the company’s corporate profile. The group also runs technology solutions such as practice management software, which aims to lock in customers and provide recurring, service-based income streams alongside physical product sales.

Where the Henry Schein shares trade today

The Henry Schein shares (US42548G1040) trade on NASDAQ under the ticker HSIC; as of 2026-06-23, 14:00 UTC they last changed hands at 78.50 US dollars.

This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell any security, or any other form of financial guidance. Investors should conduct their own research or consult a qualified advisor before making investment decisions.